Médecine

Paramédical

Autres domaines


Suscribirse

Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients? - 17/01/21

Doi : 10.1016/j.biopha.2020.111143 
Lucas Amaral-Machado a, Wógenes N. Oliveira b, Victor M. Rodrigues b, Nathan A. Albuquerque b, Éverton N. Alencar a, Eryvaldo S.T. Egito a, b,
a Department of Pharmacy, Dispersed Systems Laboratory (LaSiD), Federal University of Rio Grande Do Norte (UFRN), 59012-570, Natal, RN, Brazil 
b Graduate Program in Health Sciences, UFRN, 59012-570, Natal, RN, Brazil 

Corresponding author at: Laboratório de Sistemas Dispersos, Departamento de Farmácia, Universidade Federal do Rio Grande do Norte, Rua Jaguarari, 4985 – Apt. 1603D, 59054-500, Natal, RN, Brazil.Laboratório de Sistemas DispersosDepartamento de FarmáciaUniversidade Federal do Rio Grande do NorteRua Jaguarari4985 – Apt. 1603DNatalRN59054-500Brazil

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Graphical abstract




El texto completo de este artículo está disponible en PDF.

Highlights

Acute respiratory distress syndrome (ARDS) has drawn attention due to its relationship with death in COVID-19 patients.
No drug therapy was, yet, well-established to treat ARDS in COVID-19 patients.
Pharmaceutical active natural products with anti-inflammatory properties could prevent ARDS progression in COVID-19 patients.

El texto completo de este artículo está disponible en PDF.

Abstract

Background

The ARDS (Acute Respiratory Distress Syndrome) is a severe respiratory syndrome that was recently associated as the main death cause in the COVID-19 pandemic outbreak. Hence, in order to prevent ARDS, the pulmonary function maintenance has been the target of several pharmacological approaches. However, there is a lack of reports regarding the use of effective pharmaceutical active natural products (PANPs) for early treatment and prevention of COVID-19-related ARDS. Therefore, the aim of this work was to conduct a systematic review regarding the PANPs that could be further studied as alternatives to prevent ARDS. Consequently, this work can pave the way to spread the use of PANPs on the prevention of ARDS in COVID-19-confirmed or -suspected patients.

Methods

The search strategy included scientific studies published in English from 2015 to 2020 that promoted the elucidation of anti-inflammatory pathways targeting ARDS by in vitro and/or in vivo experiments using PANPs. Then, 74 studies regarding PANPs, able to maintain or improve the pulmonary function, were reported.

Conclusions

The PANPs may present different pulmonary anti-inflammatory pathways, wherein (i) reduction/attenuation of pro-inflammatory cytokines, (ii) increase of the anti-inflammatory mediators’ levels, (iii) pulmonary edema inhibition and (iv) attenuation of lung injury were the most observed biological effects of such products in in vitro experiments or in clinical studies. Finally, this work highlighted the PANPs with promising potential to be used on respiratory syndromes, allowing their possible use as alternative treatment at the prevention of ARDS in COVID-19-infected or -suspected patients.

El texto completo de este artículo está disponible en PDF.

Keywords : ARDS prevention, Natural products, Immunomodulation, COVID-19


Esquema


© 2020  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 134

Artículo 111143- février 2021 Regresar al número
Artículo precedente Artículo precedente
  • Mechanisms underlie the proconvulsant effects of sildenafil
  • Mohammad Reza Zirak, Reza Rahimian, Kazem Mousavizadeh, Ahmad Reza Dehpour
| Artículo siguiente Artículo siguiente
  • Lipid-based nanocarriers co-loaded with artemether and triglycerides of docosahexaenoic acid: Effects on human breast cancer cells
  • Elisa Gomes Lanna, Raoni Pais Siqueira, Marina Guimarães Carvalho Machado, Aline de Souza, Izabel Cristina Trindade, Renata Tupinambá Branquinho, Vanessa Carla Furtado Mosqueira

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.